Cargando…

Hypoxia-Inducible Factor-1 Alpha Expression Is Predictive of Pathological Complete Response in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy

SIMPLE SUMMARY: Standard neoadjuvant chemotherapy, based on taxanes and anthracyclines, makes conservative treatment of breast cancer possible and it allows for the evaluation of the tumor response in terms of achieving pathological complete response. Whereas hypoxia participates in carcinogenesis,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramírez-Tortosa, César L., Alonso-Calderón, Rubén, Gálvez-Navas, José María, Pérez-Ramírez, Cristina, Quiles, José Luis, Sánchez-Rovira, Pedro, Jiménez-Morales, Alberto, Ramírez-Tortosa, MCarmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656699/
https://www.ncbi.nlm.nih.gov/pubmed/36358811
http://dx.doi.org/10.3390/cancers14215393
_version_ 1784829501631365120
author Ramírez-Tortosa, César L.
Alonso-Calderón, Rubén
Gálvez-Navas, José María
Pérez-Ramírez, Cristina
Quiles, José Luis
Sánchez-Rovira, Pedro
Jiménez-Morales, Alberto
Ramírez-Tortosa, MCarmen
author_facet Ramírez-Tortosa, César L.
Alonso-Calderón, Rubén
Gálvez-Navas, José María
Pérez-Ramírez, Cristina
Quiles, José Luis
Sánchez-Rovira, Pedro
Jiménez-Morales, Alberto
Ramírez-Tortosa, MCarmen
author_sort Ramírez-Tortosa, César L.
collection PubMed
description SIMPLE SUMMARY: Standard neoadjuvant chemotherapy, based on taxanes and anthracyclines, makes conservative treatment of breast cancer possible and it allows for the evaluation of the tumor response in terms of achieving pathological complete response. Whereas hypoxia participates in carcinogenesis, resulting in less differenced tumor cells and poorer prognosis, HIF-1α could be predictive of the tumor response to treatment. Nonetheless, very few studies have evaluated the predictive value of HIF-1α in breast cancer in patients receiving neoadjuvant chemotherapy. ABSTRACT: To demonstrate the value of hypoxia-inducible factor-1α (HIF-1α) in predicting response in patients with breast cancer receiving standard neoadjuvant chemotherapy (NAC). Methods: Ninety-five women enrolled in two prospective studies underwent biopsies for the histopathological diagnosis of breast carcinoma before receiving NAC, based on anthracyclines and taxanes. For expression of HIF-1α, EGFR, pAKT and pMAPK, tumor samples were analyzed by immunohistochemistry in tissues microarrays. Standard statistical methods (Pearson chi-square test, Fisher exact test, Kruskal–Wallis test, Mann–Whitney test and Kaplan–Meier method) were used to study the association of HIF-1α with tumor response, survival and other clinicopathologic variables/biomarkers. Results: HIF-1α expression was positive in 35 (39.7%) cases and was significantly associated to complete pathological response (pCR) (p = 0.014). HIF-1α expression was correlated positively with tumor grade (p = 0.015) and Ki-67 expression (p = 0.001) and negativity with progesterone receptors (PR) (p = 0.04) and luminal A phenotype expression (p = 0.005). No correlation was found between HIF-1α expression and EGFR, pAKT and pMAPK. In terms of survival, HIF-1α expression was associated with a significantly shorter disease-free survival (p = 0.013), being identified as an independent prognostic factor in multivariate analysis. Conclusions: Overexpression of HIF-1α is a predictor of pCR and shorter DFS; it would be valuable to confirm these results in prospective studies.
format Online
Article
Text
id pubmed-9656699
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96566992022-11-15 Hypoxia-Inducible Factor-1 Alpha Expression Is Predictive of Pathological Complete Response in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy Ramírez-Tortosa, César L. Alonso-Calderón, Rubén Gálvez-Navas, José María Pérez-Ramírez, Cristina Quiles, José Luis Sánchez-Rovira, Pedro Jiménez-Morales, Alberto Ramírez-Tortosa, MCarmen Cancers (Basel) Article SIMPLE SUMMARY: Standard neoadjuvant chemotherapy, based on taxanes and anthracyclines, makes conservative treatment of breast cancer possible and it allows for the evaluation of the tumor response in terms of achieving pathological complete response. Whereas hypoxia participates in carcinogenesis, resulting in less differenced tumor cells and poorer prognosis, HIF-1α could be predictive of the tumor response to treatment. Nonetheless, very few studies have evaluated the predictive value of HIF-1α in breast cancer in patients receiving neoadjuvant chemotherapy. ABSTRACT: To demonstrate the value of hypoxia-inducible factor-1α (HIF-1α) in predicting response in patients with breast cancer receiving standard neoadjuvant chemotherapy (NAC). Methods: Ninety-five women enrolled in two prospective studies underwent biopsies for the histopathological diagnosis of breast carcinoma before receiving NAC, based on anthracyclines and taxanes. For expression of HIF-1α, EGFR, pAKT and pMAPK, tumor samples were analyzed by immunohistochemistry in tissues microarrays. Standard statistical methods (Pearson chi-square test, Fisher exact test, Kruskal–Wallis test, Mann–Whitney test and Kaplan–Meier method) were used to study the association of HIF-1α with tumor response, survival and other clinicopathologic variables/biomarkers. Results: HIF-1α expression was positive in 35 (39.7%) cases and was significantly associated to complete pathological response (pCR) (p = 0.014). HIF-1α expression was correlated positively with tumor grade (p = 0.015) and Ki-67 expression (p = 0.001) and negativity with progesterone receptors (PR) (p = 0.04) and luminal A phenotype expression (p = 0.005). No correlation was found between HIF-1α expression and EGFR, pAKT and pMAPK. In terms of survival, HIF-1α expression was associated with a significantly shorter disease-free survival (p = 0.013), being identified as an independent prognostic factor in multivariate analysis. Conclusions: Overexpression of HIF-1α is a predictor of pCR and shorter DFS; it would be valuable to confirm these results in prospective studies. MDPI 2022-11-02 /pmc/articles/PMC9656699/ /pubmed/36358811 http://dx.doi.org/10.3390/cancers14215393 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ramírez-Tortosa, César L.
Alonso-Calderón, Rubén
Gálvez-Navas, José María
Pérez-Ramírez, Cristina
Quiles, José Luis
Sánchez-Rovira, Pedro
Jiménez-Morales, Alberto
Ramírez-Tortosa, MCarmen
Hypoxia-Inducible Factor-1 Alpha Expression Is Predictive of Pathological Complete Response in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy
title Hypoxia-Inducible Factor-1 Alpha Expression Is Predictive of Pathological Complete Response in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy
title_full Hypoxia-Inducible Factor-1 Alpha Expression Is Predictive of Pathological Complete Response in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy
title_fullStr Hypoxia-Inducible Factor-1 Alpha Expression Is Predictive of Pathological Complete Response in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy
title_full_unstemmed Hypoxia-Inducible Factor-1 Alpha Expression Is Predictive of Pathological Complete Response in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy
title_short Hypoxia-Inducible Factor-1 Alpha Expression Is Predictive of Pathological Complete Response in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy
title_sort hypoxia-inducible factor-1 alpha expression is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656699/
https://www.ncbi.nlm.nih.gov/pubmed/36358811
http://dx.doi.org/10.3390/cancers14215393
work_keys_str_mv AT ramireztortosacesarl hypoxiainduciblefactor1alphaexpressionispredictiveofpathologicalcompleteresponseinpatientswithbreastcancerreceivingneoadjuvantchemotherapy
AT alonsocalderonruben hypoxiainduciblefactor1alphaexpressionispredictiveofpathologicalcompleteresponseinpatientswithbreastcancerreceivingneoadjuvantchemotherapy
AT galveznavasjosemaria hypoxiainduciblefactor1alphaexpressionispredictiveofpathologicalcompleteresponseinpatientswithbreastcancerreceivingneoadjuvantchemotherapy
AT perezramirezcristina hypoxiainduciblefactor1alphaexpressionispredictiveofpathologicalcompleteresponseinpatientswithbreastcancerreceivingneoadjuvantchemotherapy
AT quilesjoseluis hypoxiainduciblefactor1alphaexpressionispredictiveofpathologicalcompleteresponseinpatientswithbreastcancerreceivingneoadjuvantchemotherapy
AT sanchezrovirapedro hypoxiainduciblefactor1alphaexpressionispredictiveofpathologicalcompleteresponseinpatientswithbreastcancerreceivingneoadjuvantchemotherapy
AT jimenezmoralesalberto hypoxiainduciblefactor1alphaexpressionispredictiveofpathologicalcompleteresponseinpatientswithbreastcancerreceivingneoadjuvantchemotherapy
AT ramireztortosamcarmen hypoxiainduciblefactor1alphaexpressionispredictiveofpathologicalcompleteresponseinpatientswithbreastcancerreceivingneoadjuvantchemotherapy